SENSEX 77414.92 ▼ (0.25%)
BSE BANKEX 59542.38 ▲ (0.36%)

MANGALAM DRUGS & ORGANICS

BSE: 532637 28 Jun 2025
Healthcare
₹ 79.68
Mangalam Drugs and Organics Ltd. specializes in Pharmaceuticals within the Healthcare sector.

MANGALAM DRUGS & ORGANICS - Share Price & Details

Market Cap
₹127.0
High /Low
145.0 / 70.1
Stock P/E
18.9
Book Value
₹94.1
Dividend Yield
0.0
ROCE
8.22
ROE
₹4.72
Face Value
10.0
PEG Ratio
NA
EVEBITDA
₹5.88
Debt
89.2
CMP / FCF
NA
Debt to equity
₹0.6
NP Ann
6.72
High price all time
442.0
Piotroski score
₹6.0
Graham Number
94.8
No. Eq. Shares
1.58
Net CF
₹1.41
Net profit
6.72
Price to book value
0.85
Interest Coverage
₹1.32
Low price all time
3.43
Industry PE
32.7
Reserves
₹133
Free Cash Flow
₹23.1

Price Chart


Volume Chart


Peer Comparison

Stock Total Income Net Profit Net Sales EPS Market Cap (in Cr) P/E
LOOKS HEALTH SERVICES LIMITEDNANANANA5.11256.0
Triochem Products Ltd.,NANANANA0
MANGALAM DRUGS & ORGANICS LTD.729.041.51730.390.1127.018.9
TAKE SOLUTIONS LTD.NANANANA126171.0
PARNAX LAB LTD.NANANANA11610.0

Peer Comparison Chart


About MANGALAM DRUGS & ORGANICS

Mangalam Drugs and Organics Ltd., with Security Code 532637, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.


Latest News

Has Mangalam Drugs declared dividend?

(07 Jun 2025)
Yes, Mangalam Drugs and Organics Ltd declared a 5% dividend (0.5 per share) with an ex-date of December 21, 2017.
Read more →

How has been the historical performance of the Mangalam Drugs?

(07 Jun 2025)
Mangalam Drugs showed improved financial performance from March 2024 to March 2025, with net sales decreasing to Rs 318.23 crore but...
Read more →

Mangalam Drugs and Organics consolidated net profit declines 98.30% in the March 2025 quarter

(19 May 2025)
Sales decline 28.61% to Rs 72.78 crore. Net profit of Mangalam Drugs and Organics declined 98.30% to Rs 0.06 crore in the quarter ended March 2025 as...
Read more →

Mangalam Drugs & Organics Full Year 2025 Earnings: EPS: ₹4.25 (vs ₹5.73 loss in FY 2024)

(19 May 2025)
Mangalam Drugs & Organics ( NSE:MANGALAM ) Full Year 2025 Results Key Financial Results Revenue: ₹3.18b (down 13% from...
Read more →

Mangalam Drugs Reports Significant Financial Decline, Facing Profitability Challenges in May 2025

(19 May 2025)
Mangalam Drugs and Organics has reported its financial results for the quarter ending March 2025, revealing a decline in Profit After Tax to...
Read more →

MANGALAM DRUGS AND ORGANICS ANNOUNCES BOARD MEETING DATE

(16 May 2025)
Mangalam Drugs and Organics will hold a meeting of the Board of Directors of the Company on 17 May 2025.
Read more →